Infinity Announces Phase I Data from IPI-145 Against R/R Lymphomas

At the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Infinity Pharmaceuticals announced updated Phase 1 data from an ongoing study of IPI-145, the company's potent oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients diagnosed with relapsed or refractory B-cell or T-cell non-Hodgkin's lymphoma as well as Hodgkin's lymphoma.

Preliminary data indicates that IPI-145 is both well-tolerated and clinically active in patients with subtypes including some indolent non-Hodgkin's lymphomas, T-cell lymphoma, mantle cell lymphoma (MCL) and Hodgkin's lymphoma (HL).

Said trial investigator Steven Horwitz, MD, assistant attending physician in the department of medicine at the Memorial Sloan-Kettering Cancer Center:

I’m encouraged by the early data seen in this Phase 1 study of IPI-145. So far, IPI-145 appears to be well tolerated, with responses seen across a broad range of B-cell and T-cell lymphomas. Many hematologic malignancies are difficult to treat and new agents are clearly needed. Targeted therapies, including IPI-145, have the potential not only to add therapeutic options for our patients but also to reduce or delay the need for chemotherapy, possibly changing the way many of these malignancies are treated.

It wasn't Infinity's only presentation. The company also announced that that its Phase 2 study of IPI-145 in hematologic malignancies is open for enrollment. This trial will be a Phase 2, open-label, single-arm study designed to evaluate the safety and efficacy of IPI-145. They are looking to enroll 120 patients with refractory indolent non-Hodgkin's lymphomas, since data from the Phase 1 study showed that 13 of 19 patients with indolent NHLs had responses to IPI-145, including three who had complete responses.

Said Julian Adams, PhD, president of research and development at Infinity:

Infinity is pleased to begin its first Phase 2 study of IPI-145 in patients with indolent non-Hodgkin lymphoma, which is supported by the early, encouraging, data from our ongoing Phase 1 study reported today at ASCO. Infinity believes IPI-145 has the potential to be the best-in-class PI3K inhibitor for the treatment of blood cancers, and we are rapidly advancing IPI-145 in the clinic with a goal of addressing significant medical needs.

Source: ASCO '13

More Articles

More Articles

Lymphoma patients may have the option to participate in clinical trials, gaining access to an experimental treatment before it is widely available...

Since there are several subtypes of T cell lymphoma, there will necessarily be several non-specific T cell lymphoma...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

After surviving lymphoma treatments, patients should be on the lookout for late effects. These are symptoms that arise well after treatment has...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Advances in the treatment of Hodgkin's lymphoma have resulted in remarkable survival rates, even for...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...

The short answer: both. Let's begin with a simple definition of radiation: Radiation is the energy emitted from an energy source. That energy...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...